The goal of the Tissue Culture Shared Service is to enhance the quality of laboratory research at the Arizona Cancer Center by providing specialized cell culture services to Cancer Center investigators. The objectives of the service include providing: 1. Cell lines for addressing cancer-related research questions; 2. Cost-effective quality control measures necessary for excellent science with in vitro cancer models; 3. Reagents for cell culture that are not commercially available or are more cost-effective when obtained through the service; 4. Consultative expertise in tissue culture; 5. Assistance to the genetically modified nice shared service in establishing knock-mice. More than 250 human tumor-derived cell lines have been established by the Tissue Culture Shared Service. Cancer Center investigators have used these in cytogenetic and molecular studies to identify genetic changes in cancer and in pharmacological studies to evaluate new chemotherapeutic agents. Cell lines from this bank also have been provided to the NCI and ATCC. This service provides cost effect mycoplasma screening of cell lines to encourage regular testing. This helps ensure that results obtained by Center investigators using in vitro models are not artifacts of mycoplasma infection. The service conducts quality assurance/quality control testing of fetal bovine serum lots. The effectiveness of different lots at supporting cell line growth relative to cost is assessed and large lot prices are then negotiated at a considerable savings to investigators. By maintaining embryonic stem cell culture for the Genetically Modified Mice Shared Service, it is anticipated that the expertise of the personnel in the Tissue Culture Shared Service will be key to the successful development of knock-out mouse models at the Arizona Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA023074-22S2
Application #
6217328
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
22
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Knudsen, Erik S; Balaji, Uthra; Mannakee, Brian et al. (2018) Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility. Gut 67:508-520
Boese, Cody J; Nye, Jonathan; Buster, Daniel W et al. (2018) Asterless is a Polo-like kinase 4 substrate that both activates and inhibits kinase activity depending on its phosphorylation state. Mol Biol Cell 29:2874-2886
Sohail, Atif; Mushtaq, Adeela; Iftikhar, Ahmad et al. (2018) Emerging immune targets for the treatment of multiple myeloma. Immunotherapy 10:265-282
Doane, Cynthia J; Patil, Karuna; Hoffman, Emely A et al. (2018) Supernumerary Incisors in CB6F1 Mice Conditioned with Chemotherapy and Total Body Irradiation before Bone Marrow Transplantation. Comp Med 68:349-352
Bea, J W; Hsu, C-H; Blew, R M et al. (2018) Use of iDXA spine scans to evaluate total and visceral abdominal fat. Am J Hum Biol 30:
Lent, Adrienne B; O'Connor, Patrick A; Reikowsky, Ryan C et al. (2018) Quit outcomes among clients ineligible for cessation medication through the state quitline: a retrospective, observational study. BMC Public Health 18:1001
Bulkley, Joanna E; McMullen, Carmit K; Grant, Marcia et al. (2018) Ongoing ostomy self-care challenges of long-term rectal cancer survivors. Support Care Cancer 26:3933-3939
Zaim, Samir Rachid; Li, Qike; Schissler, A Grant et al. (2018) Emergence of pathway-level composite biomarkers from converging gene set signals of heterogeneous transcriptomic responses. Pac Symp Biocomput 23:484-495
Kobes, Joseph E; Georgiev, George I; Louis, Anthony V et al. (2018) A Comparison of Iron Oxide Particles and Silica Particles for Tracking Organ Recellularization. Mol Imaging 17:1536012118787322
Kelly, K R; Espitia, C M; Zhao, W et al. (2018) Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia 32:230-233

Showing the most recent 10 out of 1336 publications